Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370521 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
A Phase 2 study, sponsored by Spruce Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT05370521: Clinical Trial Phase 2 study, sponsored by Spruce Biosciences.
NCT05370521 is a Phase 2 study that was terminated before completion, run by Spruce Biosciences. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370521, a Phase 2 study, was terminated before completion, sponsored by Spruce Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
Primary Outcome
To evaluate the effect of tildacerfont in changing (reducing) DHEAS in subjects with PCOS and elevated adrenal androgens
Interventions
- DRUG Placebo
- DRUG Tildacerfont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Why NCT05370521 stopped before completion
NCT05370521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05370521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05370521 about?
NCT05370521 is a clinical study titled "A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens". An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
What is the current status of trial NCT05370521?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-05-15. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05370521?
The interventions under investigation include: Placebo (DRUG), Tildacerfont (DRUG).
Who is sponsoring clinical trial NCT05370521?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05370521's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI